The GPRIN3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the HeLa cervical adenocarcinoma cell line, engineered for targeted disruption of the GPRIN3 gene. This product provides a heterogeneous loss-of-function model achieved through Cas9-mediated gene disruption within a bulk cell pool, enabling functional interrogation of GPRIN3-dependent processes without clonal selection. The polyclonal format retains genetic diversity while eliminating GPRIN3 expression across the population, offering a robust system for studying the gene’s role in cancer-relevant signaling pathways.
HeLa cells, a widely used epithelial cell line derived from Henrietta Lacks, originate from a human cervical adenocarcinoma and are immortalized, exhibiting rapid proliferation and consistent experimental properties. This host background is instrumental for cancer research, particularly in dissecting molecular mechanisms of cervical cancer progression, cell motility, and drug response. The integration of GPRIN3 knockout into HeLa cells leverages their well-characterized signaling networks and amenability to standard assays, making them an ideal platform for functional genomics and cell biology investigations.
GPRIN3 encodes a scaffold protein that functions downstream of G protein-coupled receptors (GPCRs) to organize cytoskeletal remodeling and neurite outgrowth. Mechanistically, GPRIN3 interacts with G protein alpha subunits GNAI1 and GNAO1 upon GPCR activation by agonists such as lysophosphatidic acid, and is further modulated by neurotrophins NGF and BDNF. The scaffold then recruits and activates Rho GTPases CDC42, RAC1, and RHOA, which feed into the PAK-LIMK-cofilin cascade and the MAPK1/3 (ERK) pathway. Additionally, GPRIN3 associates with GRIN1, GRIN2, and tubulin, positioning it as a key node linking extracellular signals to actin dynamics and gene expression changes.
In the HeLa cervical adenocarcinoma context, GPRIN3 dysregulation may contribute to aberrant cell migration and invasion, processes central to metastasis. By disrupting GPRIN3, this knockout model enables researchers to dissect its specific contributions to GPCR-driven cytoskeletal reorganization and MAPK signaling within a tumor-relevant background. The cells serve as a valuable tool for examining how loss of GPRIN3 affects HeLa cell morphology, motility, and signaling crosstalk, potentially revealing novel targets for inhibiting cervical cancer progression.
This polyclonal knockout cell population is suited for a broad range of experimental applications, including detailed analysis of GPCR-mediated signal transduction, quantitative assessment of cell migration using scratch wound assays, and invasion studies via Boyden chamber assays. Researchers can combine the cells with biochemical readouts such as Rho GTPase pull-down activation assays, phospho-ERK ELISA, and Western blotting for pathway components, as well as transcriptomic profiling by RNA-seq. Immunofluorescence microscopy enables visualization of cytoskeletal alterations. These tools collectively support investigations into GPRIN3’s role in cervical adenocarcinoma and neurodevelopmental processes. For further technical details or customized cell engineering solutions, please contact Ascent Research.
